

10/519,979

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:38:47 ON 16 FEB 2007)

FILE 'REGISTRY' ENTERED AT 13:39:10 ON 16 FEB 2007

L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 0 S L1 FULL
L4 STRUCTURE UPLOADED
L5 0 S L4 SSS SAM
L6 5 S L4 FULL

FILE 'CAPLUS' ENTERED AT 13:42:10 ON 16 FEB 2007



L7 7 S L6

FILE 'REGISTRY' ENTERED AT 13:44:27 ON 16 FEB 2007

L8 STRUCTURE UPLOADED
L9 0 S L8 SSS SAM
L10 4 S L8 FULL

FILE 'CAPLUS' ENTERED AT 13:45:02 ON 16 FEB 2007

L11 3 S L10



chain nodes :

24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

chain bonds :

1-25 4-27 8-18 9-28 10-26 12-33 13-35 13-37 14-36 14-38 15-39 16-40 17-29 19-32 20-31 21-24 22-30
33-34

ring bonds :

1-2 1-6 2-3 2-16 3-4 3-23 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16 15-23
17-18 17-22 18-19 19-20 20-21 21-22

exact/norm bonds :

1-25 2-16 3-23 5-7 6-10 7-8 8-9 9-10 10-26 11-12 11-16 12-13 13-14 13-37 14-15 14-38 15-16 15-23
21-24

exact bonds :



4-27 8-18 9-28 12-33 13-35 14-36 15-39 16-40 17-29 19-32 20-31 22-30 33-34

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS25:CLASS26:CLASS27:CLASS
28:CLASS29:CLASS30:CLASS31:CLASS32:CLASS33:CLASS34:CLASS35:CLASS36:CLASS37:CLASS38:CLASS39:CLASS
40:CLASS



chain nodes :

24 25 26 27 28 29 30 31 32 33 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

chain bonds :

1-25 8-18 10-26 12-27 13-29 13-31 14-30 14-32 15-33 16-34 21-24 27-28

ring bonds :

1-2 1-6 2-3 2-16 3-4 3-23 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16 15-23
17-18 17-22 18-19 19-20 20-21 21-22

exact/norm bonds :

1-25 2-16 3-23 5-7 6-10 7-8 8-9 9-10 10-26 11-12 11-16 12-13 13-14 13-31 14-15 14-32 15-16 15-23
21-24

exact bonds :



8-18 12-27 13-29 14-30 15-33 16-34 27-28

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS25:CLASS26:CLASS27:CLASS
28:CLASS29:CLASS30:CLASS31:CLASS32:CLASS33:CLASS34:CLASS



chain nodes :

23 24 25 26 27 28 30 31 32 33

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 29

chain bonds :

1-24 8-18 10-25 11-30 12-31 13-26 13-32 15-27 16-28 21-23 32-33

ring bonds :

1-2 1-6 2-3 3-4 3-29 4-5 4-15 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16 16-29
17-18 17-22 18-19 19-20 20-21 21-22

exact/norm bonds :

1-24 3-29 4-15 5-7 6-10 7-8 8-9 9-10 10-25 11-12 11-16 11-30 12-13 12-31 13-14 14-15 15-16 16-29
21-23

exact bonds :

8-18 13-26 13-32 15-27 16-28 32-33

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:CLASS24:CLASS25:CLASS26:CLASS
27:CLASS28:CLASS29:Atom 30:CLASS31:CLASS32:CLASS33:CLASS

10/519,979

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:38:47 ON 16 FEB 2007

=> file req

McIntosh

10/519,979

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 13:39:10 ON 16 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2007 HIGHEST RN 921436-24-0
DICTIONARY FILE UPDATES: 15 FEB 2007 HIGHEST RN 921436-24-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10519979.str

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam
SAMPLE SEARCH INITIATED 13:39:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 100 TO ITERATE

100.0% PROCESSED 100 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 1401 TO 2599
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 13:39:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2042 TO ITERATE

100.0% PROCESSED 2042 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10519979a.str

L4 STRUCTURE UPLOADED

=> s 14 sss sam
SAMPLE SEARCH INITIATED 13:41:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 100 TO ITERATE

100.0% PROCESSED 100 ITERATIONS 0 ANSWERS

McIntosh

10/519, 979

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1401 TO 2599
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s 14 full
FULL SEARCH INITIATED 13:41:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2042 TO ITERATE


100.0% PROCESSED 2042 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

L6 5 SEA SSS FUL L4

=> d scan 1-5 16
'1-5' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

L6 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H,10H-Pyran[2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-
methoxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI)
MF C22 H20 O9

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)

McIntosh

10/519,979

IND -- Index Data

IPC -- International Patent Classification

PATS -- PI, SO

STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels

IBIB -- BIB, indented, with text labels

ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)

OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations

SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.

HELP FORMATS -- To see detailed descriptions of the predefined formats.


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L6 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 2H,10H-Pyran[2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
3,4,4a,11b-tetrahydro-11-methoxy-3,4-bis(phenylmethoxy)-2-
[(phenylmethoxy)methyl]-8-[4-(phenylmethoxy)phenyl]-, (2R,3R,4S,4aR,11bS)-
(9CI)

MF C50 H44 O9

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 2H,10H-Pyran[2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-[4-
(methoxymethoxy)phenyl]-, (2R,3S,4S,4aS,11bS)- (9CI)

MF C23 H22 O10

Absolute stereochemistry.




McIntosh

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2H,10H-Pyran-2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
 3,4,4a,11b-tetrahydro-11-methoxy-8-(4-methoxyphenyl)-3,4-
 bis(phenylmethoxy)-2-[(phenylmethoxy)methyl]-, (2R,3R,4S,4aR,11bS)- (9CI)
 MF C44 H40 O9


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2H,10H-Pyran-2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-
 hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI)
 MF C21 H18 O9

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

| => file caplus | | | |
|----------------------|------------|---------|--------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL | |
| FULL ESTIMATED COST | ENTRY | SESSION | |
| | | 345.55 | 345.76 |

FILE 'CAPLUS' ENTERED AT 13:42:10 ON 16 FEB 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Feb 2007 VOL 146 ISS 9
FILE LAST UPDATED: 15 Feb 2007 (20070215/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 13:38:47 ON 16 FEB 2007)

FILE 'REGISTRY' ENTERED AT 13:39:10 ON 16 FEB 2007

L1 STRUCTURE uploaded
L2 0 S L1 SSS SAM
L3 0 S L1 FULL
L4 STRUCTURE uploaded
L5 0 S L4 SSS SAM
L6 5 S L4 FULL

FILE 'CAPLUS' ENTERED AT 13:42:10 ON 16 FEB 2007

=> s 16
L7 7 L6

=> d bib abs hitstr 1-7 17

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1332639 CAPLUS
DN 146:42084
TI Antitumors isolated from oolong tea leaf
IN Wakabayashi, Keiji; Nukatani, Haruo; Muto, Tomohiro
PA National Cancer Center, Japan
SO Jpn. Kokai Tokkyo Koho, 18pp.
CODEN: JKXXAF

DT Patent
LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | JP 2006342103 | A | 20061221 | JP 2005-169262 | 20050609 |
| PRAI | JP 2005-169262 | | | | |

AB The antitumoric OTAC (Oolong tea active compound), flavone derivs., are extracted from Oolong tea leaf. The antitumoric OTAC are able to inhibit cancer in rat colonic aberrant crypt foci (ACF model) and colonic polyp-formation Apc gene-deficient mouse model. Extraction of the antitumoric OTAC from the oolong tea leaf with hot water and inhibition of cancer in the two animal models were shown.

IT 720684-57-1P


RL: FFD (Food or feed use); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(OTAC antitumors isolated from oolong tea leaf)

RN 720684-57-1 CAPLUS


CN 2H,10H-Pyran[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:441728 CAPLUS
 DN 145:347946
 TI Inhibition of intestinal carcinogenesis by a new flavone derivative, Chafurosode, in oolong tea
 AU Niho, Naoko; Mutoh, Michihiro; Sakano, Katsuhisa; Takahashi, Mami; Hirano, Sachiko; Nukaya, Haruo; Sugimura, Takashi; Wakabayashi, Keiji
 CS Cancer Prevention Basic Research Project, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
 SO Cancer Science (2006), 97(4), 248-251
 CODEN: CSACCM; ISSN: 1347-9032
 PB Blackwell Publishing Asia Pty Ltd.
 DT Journal
 LA English
 AB A new flavone derivative, Chafurosode, has been isolated as a strong anti-inflammatory compound from oolong tea leaves, and its structure determined to be (2R,3S,4S,4aS,11bS)-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-3,4,4a,11b-tetrahydro-2H,10H-pyran[2',3':4,5]furo[3,2-g]chromen-10-one. To assess its potential to inhibit intestinal carcinogenesis, 2.5, 5, and 10 ppm Chafurosode was given in the diet to Apc-deficient Min mice for 14 wk from 6 wk of age. Total nos. of polyps were reduced to 83, 73, and 56% of the control value, resp. Moreover, dietary administration at 10 and 20 ppm reduced azoxymethane (AOM)-induced colon aberrant crypt foci (ACF) development in rats to 69% of the AOM-treated control value with the higher dose. Chafurosode-associated toxicity was not observed at 2.5-10 ppm in Min mice and 10-20 ppm in AOM-treated rats. These results suggest that Chafurosode might be a good chemopreventive agent for colon cancer.
 IT 720684-57-1, Chafurosode
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of intestinal carcinogenesis by Chafurosode in oolong tea)
 RN 720684-57-1 CAPLUS
 CN 2H,10H-Pyran[2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:1196260 CAPLUS
 DN 143:440151
 TI Preparation of flavone C glycoside
 IN Tsuji, Kunio; Tanaka, Kei; Nukatani, Haruo; Furuta, Takumi
 PA Japan Science and Technology Agency, Japan
 SO Jpn. Kokai Tokkyo Koho, 14 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | JP 2005314260 | A | 20051110 | JP 2004-132592 | 20040428 |
| PRAI | JP 2004-132592 | | 20040428 | | |
| OS | MARPAT 143:440151 | | | | |
| GI | | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compound I, which was isolated as antiallergy agent from oolong tea extract, is prepared by condensation of resorcinols II [R1, R2 = H, protecting group; R3 = (protected) OH, ether group, ester group; R4 = H, CO; when R3 = ether group and R4 = CO; then R3R4 may form (un)substituted ring] with sugars III (R5 = H, protecting group; R6 = halo, OC:NHCX3; X = halo) in the presence of Lewis acid catalysts in aprotic solvents and by treatment of C glycosides IV (R7, R8 = similar group as in R1, R2; R9, R10 = similar group as in R3, R4) with azodicarboxamide or azodicarboxylate esters and trialkylphosphine, triarylphosphine, or phosphoranes in aprotic solvents. Thus, 4-benzyloxy-2,6-dihydroxyacetophenone was treated with O-(2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyloxy)trichloroacetimidate in the presence of TMSOTf in CH₂Cl₂, esterified with 4-methoxymethoxybenzoic acid, cyclized, debenzylated, treated with TMAD and Bu₃P in THF, and deprotected to give I.


IT 791601-83-7P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of flavone C glycoside from resorcinols and sugars)

BN 791601-83-7 CAPIUS (preparation of)

RN 791601-83-7 CAPlus
 CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-[4-
 (methoxymethoxy)phenyl]- (2R,3S,4S,11bS)- (8CI) (CA INDEX NAME)

Absolute stereochemistry




IT 720684-57-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

Preparation

720684-57-1 CAPLUS
 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
 .3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-
 hydroxyphenyl)-1-(2S,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry - Rotation (-)



L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1103788 CAPLUS

AN 2005.11057
RN 143:386847

TI Process for producing flavone c glycoside derivatives

IN Process for producing flavor
IN Tsuji, Kuniro; Nukaya, Haruo

PA Suntory Limited, Japan

SO PCT Int. Appl



CODEN:

DT Patent

LA Japa

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2005095416 | A1 | 20051013 | WO 2005-JP5695 | 20050328 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| JP 2005289888 | A | 20051020 | JP 2004-107760 | 20040331 |
| CA 2561401 | A1 | 20051013 | CA 2005-2561401 | 20050328 |
| EP 1731522 | A1 | 20051213 | EP 2005-721621 | 20050328 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| PRAI JP 2004-107760 | A | 20040331 | | |
| WO 2005-JP5695 | W | 20050328 | | |

GI



AB This invention provided a process for efficiently producing a flavone C glycoside derivative represented by the formula I which is an antiallergic substance or its salt, or a flavone C glycoside derivative represented by the formula II or its salt. I and II can be easily and efficiently synthesized by using isovitexin and vitexin contained in herbs and so on as the starting materials reacted in the presence of dehydrating agent, such as 1,1'-azobis[N,N-dimethylformamide] and tri-n-butylphosphine.


IT 720684-57-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of flavone c glycoside derivs. by cyclization of (iso)vitexin)

RN 720684-57-1 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-
hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:902389 CAPLUS
DN 141:380099
TI Flavone derivatives and process for producing them
IN Nakatsuka, Takashi
PA Daiichi Suntory Pharma Co., Ltd., Japan; Daiichi Suntory Biomedical Research Co., Ltd.
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2004092180 | A1 | 20041028 | WO 2004-JP5451 | 20040416 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| JP 2006176407 | A | 20060706 | JP 2003-113976 | 20030418 |
| PRAI JP 2003-113976 | A | 20030418 | | |
| OS MARPAT 141:380099 | | | | |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB A process for the production of flavone derivs. I [R1a, R1b, R1c, R1m and R1n = H, OH, etc.], intermediates for the production thereof; and processes for producing the intermediates were disclosed. Further, the invention provides compds. I [R1a, R1b, R1c, R1m and R1n = H, OH, etc.], (with the proviso that the compound wherein R1c is OH, R1a, R1b, R1m, and R1n are hydrogen, and the sugar moiety is D-mannose is excepted), pharmacol. acceptable salts thereof, and pharmaceutical compns. containing both. For example, treatment of a mixture of compound II, III (35 mg), e.g., prepared from Me 3,4,5-tri-O-benzyl-2-O-p-nitrobenzyl-D-glucopyranoside in 10 steps, with trimethylsilyl triflate at room temperature for 10 min afforded compound IV [R1a = R1b = R1c = R1m = H] (8 mg), converted to compound I [R1a = R1b = R1c = R1m = R1n = H] using BC13. In contact dermatitis control test, compound I [R1a = R1b = R1c = R1m = R1n = H] exhibited p<0.05 (Dunnett's test) at ≥2 µg/kg dose. Disclosed compds. I are claimed useful for the treatment of inflammation, allergy. Formulation is given.
IT 780789-07-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(flavone scaffold preparation using iodobenzene diacetate)
RN 780789-07-3 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-11-methoxy-8-(4-methoxyphenyl)-3,4-bis(phenylmethoxy)-2-[(phenylmethoxy)methyl]-, (2R,3R,4S,4aR,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 720684-64-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (flavone scaffold preparation via heterocyclization using trimethylsilyl
 triflate)
 RN 720684-64-0 CAPLUS
 CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
 3,4,4a,11b-tetrahydro-11-methoxy-3,4-bis(phenylmethoxy)-2-
 [(phenylmethoxy)methyl]-8-[4-(phenylmethoxy)phenyl]-, (2R,3R,4S,4aR,11bS)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 720684-57-1P 780789-12-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of flavone derivs. for treatment of inflammation, allergy)
 RN 720684-57-1 CAPLUS
 CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-
 hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 780789-12-0 CAPLUS
 CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-
 methoxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:769344 CAPLUS
 DN 141:411155
 TI Concise total synthesis of flavone C-glycoside having potent anti-inflammatory activity
 AU Furuta, Takumi; Kimura, Tomoyuki; Kondo, Sachiko; Mihara, Hisashi; Wakimoto, Toshiyuki; Nukaya, Haruo; Tsuji, Kuniro; Tanaka, Kiyoshi
 CS School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, 422-8526, Japan
 SO Tetrahedron (2004), 60(42), 9375-9379
 CODEN: TETRAB; ISSN: 0040-4020
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 141:411155
 AB The total synthesis of anti-inflammatory active flavone C-glycoside isolated from oolong tea extract is achieved. Introducing a C-glucosyl moiety to an aryl system and constructing a fused tetracyclic ring characteristic to this natural product were conducted based on the O-to-C rearrangement of sugar moiety and the successive intramol. Mitsunobu reaction, resp. This concise and efficient synthetic pathway is applicable to the large-scale synthesis of target flavone and for constructing a large library of related compds.
 IT 791601-83-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of the anti-inflammatory active flavone C-glycoside isolated from oolong tea extract via rearrangement and intramol. Mitsunobu reaction)
 RN 791601-83-7 CAPLUS
 CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-[4-(methoxymethoxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 720684-57-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of the anti-inflammatory active flavone C-glycoside isolated from oolong tea extract via rearrangement and intramol. Mitsunobu reaction)
 RN 720684-57-1 CAPLUS
 CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:403848 CAPLUS

DN 141:106296

TI First total synthesis of structurally unique flavonoids and their strong anti-inflammatory effect

AU Nakatsuka, Takashi; Tomimori, Yoshiaki; Fukuda, Yoshiaki; Nukaya, Haruo
CS Daiichi Suntory Biomedical Research Co., Ltd., Mishima-gun, Osaka,
618-8513, Japan

SO Bioorganic & Medicinal Chemistry Letters (2004), 14(12), 3201-3203
CODEN: BMCLE8; ISSN: 0960-894X


PB Elsevier Science B.V.

DT Journal

LA English

OS CASREACT 141:106296

GI



AB The first total synthesis of structurally unique flavonoids I (R = OH, H) is described. These compds. showed very strong anti-inflammatory effect against delayed hypersensitivity in a mouse model.


IT 720684-57-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of fused tricyclic flavonoids from a D-glucal and their strong anti-inflammatory effect)

RN 720684-57-1 CAPLUS

CN 2H,10H-Pyranoc[2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



10/519,979

IT 720684-64-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of fused tricyclic flavonoids from a D-glucal and their strong
anti-inflammatory effect)
RN 720684-64-0. CAPLUS
CN 2H,10H-Pyran-2',3':4,5]furo[3,2-g][1]benzopyran-10-one,
3,4,4a,11b-tetrahydro-11-methoxy-3,4-bis(phenylmethoxy)-2-
[(phenylmethoxy)methyl]-8-[4-(phenylmethoxy)phenyl]-, (2R,3R,4S,4aR,11bS)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

| | | | |
|--|------------|---------|--|
| => file reg | | | |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL | |
| FULL ESTIMATED COST | ENTRY | SESSION | |
| | 38.77 | 384.53 | |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL | |
| CA SUBSCRIBER PRICE | ENTRY | SESSION | |
| | -5.46 | -5.46 | |

FILE 'REGISTRY' ENTERED AT 13:44:27 ON 16 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2007 HIGHEST RN 921436-24-0
DICTIONARY FILE UPDATES: 15 FEB 2007 HIGHEST RN 921436-24-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10519979b.str

L8 STRUCTURE UPLOADED

=> s 18 sss sam
SAMPLE SEARCH INITIATED 13:44:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 100 TO ITERATE

100.0% PROCESSED 100 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

McIntosh

10/519,979

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1401 TO 2599
PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L8

=> s 18 full
FULL SEARCH INITIATED 13:44:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2042 TO ITERATE

100.0% PROCESSED 2042 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L10 4 SEA SSS FUL L8

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 172.10 556.63
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -5.46

FILE 'CAPLUS' ENTERED AT 13:45:02 ON 16 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Feb 2007 VOL 146 ISS 9
FILE LAST UPDATED: 15 Feb 2007 (20070215/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 110
L11 3 L10

=> d bib abs hitstr 1-3 111

L11 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1332639 CAPLUS
DN 146:42084
TI Antitumors isolated from oolong tea leaf
IN Wakabayashi, Keiji; Nukatani, Haruo; Muto, Tomohiro
PA National Cancer Center, Japan
SO Jpn. Kokai Tokkyo Koho, 18pp.
CODEN: JKXXAF

DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | JP 2006342103 | A | 2006/221 | JP 2005-169262 | 20050609 |
| PRAI | JP 2005-169262 | | 20050609 | | |


AB The antitumoric OTAC (Oolong tea active compound), flavone derivs., are extracted from Oolong tea leaf. The antitumoric OTAC are able to inhibit cancer in rat colonic aberrant crypt foci (ACF model) and colonic polyp-formation Apc gene-deficient mouse model. Extraction of the antitumoric OTAC from the oolong tea leaf with hot water and inhibition of cancer in the two animal models were shown.

McIntosh

10/519, 979

IT 866737-00-0P
RL: FFD (Food or feed use); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(OTAC antitumors isolated from oolong tea leaf)
RN 866737-00-0 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one,
7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-hydroxyphenyl)-, (7aS,8S,9S,10R,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:36756 CAPLUS
DN 144:108139
TI Preparation of flavones, their medial compositions, and their use as antiallergy and anti-inflammatory agents
IN Nakatsuka, Takashi; Nimura, Junko
PA Daiichi Asbio Pharma Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
----- ----- ----- -----
PI JP 2006008626 A 20060112 JP 2004-190367 20040628
PRAI JP 2004-190367 20040628
OS MARPAT 144:108139
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Flavones I [R1a-R1e = H, OH, C1-6 linear or branched alkyl(oxy), halo] and their pharmacol. acceptable salts are prepared from p-azidobenzoyloxyfluoropyrans II (R3a-xirc = protecting group) and 2-hydroxyacetophenones III (R3d, R3e = protecting group) in the presence of Lewis acids via IV (R3a-R3e = protecting group; R3f = p-nitrobenzyl, p-azidobenzyl). Thus, cyclization of 8-[(2S,3S,4R,5R,6R)-4,5-bis(benzyloxy)-6-benzyloxymethyl-3-hydroxytetrahydro-2H-pyran-2-yl]-5,7-dihydroxy-2-phenyl-4H-chromen-4-one gave (7aR,8S,9R,10R,11aS)-8,9-bis(benzyloxy)-10-(benzyloxy)methyl-5-hydroxy-2-phenyl-7a,9,10,11a-tetrahydro-4H,8H-pyrano[2',3':4,5]furo[2,3-h]chromen-4-one, which was deprotected to afford the corresponding flavone derivative. The product inhibited the ear swelling of in mice with TNCB-induced contact dermatitis in a dose-dependent manner.
IT 866737-00-0P 873077-63-5P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of flavones as antiallergy and anti-inflammatory agents)

10/519, 979

RN 866737-00-0 CAPLUS

CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one,
7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-
hydroxyphenyl)-, (7aS,8S,9S,10R,11aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 873077-63-5 CAPLUS

CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one,
7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-
methoxyphenyl)-, (7aS,8S,9S,10R,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 873077-34-0P 873077-51-1P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of flavones as antiallergy and anti-inflammatory agents)

RN 873077-34-0 CAPLUS


CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one,
7a,9,10,11a-tetrahydro-5-hydroxy-2-(4-hydroxyphenyl)-8,9-
bis(phenylmethoxy)-10-[(phenylmethoxy)methyl]-, (7aR,8S,9R,10R,11aS)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 873077-51-1 CAPLUS
 CN 4H,8H-Pyranoc[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one,
 7a,9,10,11a-tetrahydro-5-hydroxy-2-(4-methoxyphenyl)-8,9-
 bis(phenylmethoxy)-10-[(phenylmethoxy)methyl]-, (7aR,8S,9R,10R,11aS)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:1103788 CAPLUS
 DN 143:386847
 TI Process for producing flavone C glycoside derivatives
 IN Tsuji, Kuniro; Nukaya, Haruo
 PA Suntory Limited, Japan
 SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 2005095416 | A1 | 20051013 | WO 2005-JP5695 | 20050328 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, | | | | |

MR, NE, SN, TD, TG
 JP 2005289888 A 20051020 JP 2004-107760 20040331
 CA 2561401 A1 20051013 CA 2005-2561401 20050328
 EP 1731522 A1 20061213 EP 2005-721621 20050328
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 PRAI JP 2004-107760 A 20040331
 WO 2005-JP5695 W 20050328

GI



AB This invention provided a process for efficiently producing a flavone C glycoside derivative represented by the formula I which is an antiallergic substance or its salt, or a flavone C glycoside derivative represented by the formula II or its salt. I and II can be easily and efficiently synthesized by using isovitexin and vitexin contained in herbs and so on as the starting materials reacted in the presence of dehydrating agent, such as 1,1'-azobis[N,N-dimethylformamide] and tri-n-butylphosphine.


IT 866737-00-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of flavone c glycoside derivs. by cyclization of (iso)vitexin)

RN 866737-00-0 CAPLUS

CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one,
 7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-
 hydroxyphenyl)-, (7aS,8S,9S,10R,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

McIntosh